Long-Term Outcome and Recurrence of Idiopathic Choroidal Neovascularization Treated with Intravitreal Bevacizumab.
1 Department of Ophthalmology, Kim's Eye Hospital, Konyang University College of Medicine , Seoul, South Korea .
2 Department of Ophthalmology, Konyang University College of Medicine , Daejeon, South Korea .
- Published Article
Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics
- Publication Date
Sep 01, 2016
The long-term outcome of intravitreal bevacizumab treatment for idiopathic CNV was generally favorable. Although CNV recurrence was noted in 30.8% of patients, the recurrence may not significantly influence long-term visual prognosis.
Report this publication
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
This record was last updated on 06/09/2018 and may not reflect the most current and accurate biomedical/scientific data available from NLM.
The corresponding record at NLM can be accessed at https://www.ncbi.nlm.nih.gov/pubmed/27479572